169 related articles for article (PubMed ID: 36268064)
1. Spatial heterogeneity and organization of tumor mutation burden with immune infiltrates within tumors based on whole slide images correlated with patient survival in bladder cancer.
Xu H; Clemenceau JR; Park S; Choi J; Lee SH; Hwang TH
J Pathol Inform; 2022; 13():100105. PubMed ID: 36268064
[TBL] [Abstract][Full Text] [Related]
2. Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes.
Loupakis F; Depetris I; Biason P; Intini R; Prete AA; Leone F; Lombardi P; Filippi R; Spallanzani A; Cascinu S; Bonetti LR; Maddalena G; Valeri N; Sottoriva A; Zapata L; Salmaso R; Munari G; Rugge M; Dei Tos AP; Golovato J; Sanborn JZ; Nguyen A; Schirripa M; Zagonel V; Lonardi S; Fassan M
Oncologist; 2020 Jun; 25(6):481-487. PubMed ID: 31967692
[TBL] [Abstract][Full Text] [Related]
3. Development of Prognostic Biomarkers by TMB-Guided WSI Analysis: A Two-Step Approach.
Liu X; Liu Z; Yan Y; Wang K; Wang A; Ye X; Wang L; Wei W; Li B; Sun C; He W; Zhu X; Liu Z; Liu J; Lu J; Tian J
IEEE J Biomed Health Inform; 2023 Feb; PP():. PubMed ID: 37027578
[TBL] [Abstract][Full Text] [Related]
4. Multi-omics analysis of tumor mutation burden combined with immune infiltrates in bladder urothelial carcinoma.
Zhang C; Shen L; Qi F; Wang J; Luo J
J Cell Physiol; 2020 Apr; 235(4):3849-3863. PubMed ID: 31596511
[TBL] [Abstract][Full Text] [Related]
5. Identification of NTRK3 as a potential prognostic biomarker associated with tumor mutation burden and immune infiltration in bladder cancer.
Zhang Z; Yu Y; Zhang P; Ma G; Zhang M; Liang Y; Jiao W; Niu H
BMC Cancer; 2021 Apr; 21(1):458. PubMed ID: 33894748
[TBL] [Abstract][Full Text] [Related]
6. Spatial Characterization of Tumor-Infiltrating Lymphocytes and Breast Cancer Progression.
Fassler DJ; Torre-Healy LA; Gupta R; Hamilton AM; Kobayashi S; Van Alsten SC; Zhang Y; Kurc T; Moffitt RA; Troester MA; Hoadley KA; Saltz J
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565277
[TBL] [Abstract][Full Text] [Related]
7. Deep-Learning-Based Characterization of Tumor-Infiltrating Lymphocytes in Breast Cancers From Histopathology Images and Multiomics Data.
Lu Z; Xu S; Shao W; Wu Y; Zhang J; Han Z; Feng Q; Huang K
JCO Clin Cancer Inform; 2020 May; 4():480-490. PubMed ID: 32453636
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral spatial heterogeneity of tumor-infiltrating lymphocytes is a significant factor for precisely stratifying prognostic immune subgroups of microsatellite instability-high colorectal carcinomas.
Jung M; Lee JA; Yoo SY; Bae JM; Kang GH; Kim JH
Mod Pathol; 2022 Dec; 35(12):2011-2022. PubMed ID: 35869301
[TBL] [Abstract][Full Text] [Related]
9. Histopathological characteristics and artificial intelligence for predicting tumor mutational burden-high colorectal cancer.
Shimada Y; Okuda S; Watanabe Y; Tajima Y; Nagahashi M; Ichikawa H; Nakano M; Sakata J; Takii Y; Kawasaki T; Homma KI; Kamori T; Oki E; Ling Y; Takeuchi S; Wakai T
J Gastroenterol; 2021 Jun; 56(6):547-559. PubMed ID: 33909150
[TBL] [Abstract][Full Text] [Related]
10. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
11. Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma.
Jiang T; Shi J; Dong Z; Hou L; Zhao C; Li X; Mao B; Zhu W; Guo X; Zhang H; He J; Chen X; Su C; Ren S; Wu C; Zhou C
J Hematol Oncol; 2019 Jul; 12(1):75. PubMed ID: 31299995
[TBL] [Abstract][Full Text] [Related]
12. Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies.
Voutsadakis IA
Curr Oncol; 2022 Feb; 29(3):1390-1407. PubMed ID: 35323317
[No Abstract] [Full Text] [Related]
13. Integrated analysis of tumor mutation burden and immune infiltrates in endometrial cancer.
Zhou H; Chen L; Lei Y; Li T; Li H; Cheng X
Curr Probl Cancer; 2021 Apr; 45(2):100660. PubMed ID: 33012523
[TBL] [Abstract][Full Text] [Related]
14. Distinct mutational profile and immune microenvironment in microsatellite-unstable and
Hwang HS; Kim D; Choi J
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34607897
[TBL] [Abstract][Full Text] [Related]
15. PRR11 is a prognostic biomarker and correlates with immune infiltrates in bladder urothelial carcinoma.
Ni W; Yi L; Dong X; Cao M; Zheng J; Wei Q; Yuan C
Sci Rep; 2023 Feb; 13(1):2051. PubMed ID: 36739300
[TBL] [Abstract][Full Text] [Related]
16. Exploration of the relationships between tumor mutation burden with immune infiltrates in clear cell renal cell carcinoma.
Zhang C; Li Z; Qi F; Hu X; Luo J
Ann Transl Med; 2019 Nov; 7(22):648. PubMed ID: 31930049
[TBL] [Abstract][Full Text] [Related]
17. Mining TCGA database for tumor mutation burden and their clinical significance in bladder cancer.
Lv J; Zhu Y; Ji A; Zhang Q; Liao G
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32239176
[TBL] [Abstract][Full Text] [Related]
18. Spatial analysis of tumor-infiltrating lymphocytes in histological sections using deep learning techniques predicts survival in colorectal carcinoma.
Xu H; Cha YJ; Clemenceau JR; Choi J; Lee SH; Kang J; Hwang TH
J Pathol Clin Res; 2022 Jul; 8(4):327-339. PubMed ID: 35484698
[TBL] [Abstract][Full Text] [Related]
19. Characterizing the Survival-Associated Interactions Between Tumor-Infiltrating Lymphocytes and Tumors From Pathological Images and Multi-Omics Data.
Shao W; Zuo Y; Shi Y; Wu Y; Tang J; Zhao J; Sun L; Lu Z; Sheng J; Zhu Q; Zhang D
IEEE Trans Med Imaging; 2023 Oct; 42(10):3025-3035. PubMed ID: 37159321
[TBL] [Abstract][Full Text] [Related]
20. Assessment of associations between clinical and immune microenvironmental factors and tumor mutation burden in resected nonsmall cell lung cancer by applying machine learning to whole-slide images.
Ono A; Terada Y; Kawata T; Serizawa M; Isaka M; Kawabata T; Imai T; Mori K; Muramatsu K; Hayashi I; Kenmotsu H; Ohshima K; Urakami K; Nagashima T; Kusuhara M; Akiyama Y; Sugino T; Ohde Y; Yamaguchi K; Takahashi T
Cancer Med; 2020 Jul; 9(13):4864-4875. PubMed ID: 32400056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
